Post-Hoc Assessment of Cognitive Efficacy in Alzheimer’s Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial
- 1 May 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 21 (5) , 353-365
Abstract
Background: Disease progression in Alzheimer’s Dementia (AD) is typically characterized by accelerated cognitive and functional decline, where heterogeneous trajectories can impact the observed treatment response. Methods: We hypothesized that unobserved heterogeneity could obscure treatment benefits in AD. The effect of unobserved heterogeneity was empirically quantified within the Alzheimer’s Management By Albumin Replacement (AMBAR) phase 2b trial data. The ADAS-Cog 12 cognition endpoint was reanalyzed in a 2-class latent growth mixture model initially fit to the treatment arm. The model with the best fit was then applied across both treatment arms to a larger (n=1000) simulated dataset that was representative of AMBAR trial cognitive data. Results: Two classes of patients were observed: a stable cognitive trajectory class and a highly variable class. Removal of the latter (n=48, 22%) from the analysis and refitting efficacy models comparing the stable class to full placebo yielded significant treatment efficacy on cognition (p=0.007, Cohen’s D=-0.4). Comparison of the stable class of each arm within the simulated dataset revealed a significant difference in treatment efficacy favoring the simulated stable treatment arm. Conclusion: This post hoc exploratory analysis suggests that prespecified strategies for addressing unobserved heterogeneity may yield improved effect detection in AD trials. The generalizability of the analytic strategy is limited by latent stratification in only the treatment arm, a requirement given the small placebo arm in AMBAR. This limitation was partially addressed by the simulation modeling. Clinical Trial Registration Number:: NCT01561053Keywords
This publication has 47 references indexed in Scilit:
- Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trialsAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2022
- 2021 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2021
- Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s DiseaseCell, 2020
- Detecting biological heterogeneity patterns in ADNI amnestic mild cognitive impairment based on volumetric MRIBrain Imaging and Behavior, 2020
- A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR StudyAlzheimer's & Dementia, 2020
- APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s PathogenesisMolecular Neurobiology, 2018
- A longitudinal study of cognitive trajectories and its factors for Koreans aged 60 and over: A latent growth mixture modelInternational Journal of Geriatric Psychiatry, 2018
- Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression StudyInternational Journal of Geriatric Psychiatry, 2014
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approachActa Neuropathologica, 2011
- Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practiceInternational Journal of Geriatric Psychiatry, 2006